Business
Jade Biosciences Announces $45 Million Private Placement
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Purs
About this update from Jade Biosciences, Inc.
[{"type":"image","alt":"Jade Biosciences","displaySize":"","headline":null,"caption":"Jade Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Wo31M4PemuELy9uASaVLHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/345f7337e814bf11ed72261f2fc78278","width":300,"height":112}},"lazy":false},{"type":"text","content":"SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses.","length":495,"tagName":"p"},{"type":"text","content":"Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of 3,214,286 shares of its common stock (“Common Stock”) at a purchase price of $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to satisfaction of customary closing conditions.","length":322,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds from the private placement to fund research and development, general corporate expenses, and working capital needs.","length":159,"tagName":"p"},{"type":"text","content":"The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the securities purchase agreement, Jade and BB Biotech entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of Common Stock sold in t...